keyword
MENU ▼
Read by QxMD icon Read
search

anthracycline cardio

keyword
https://www.readbyqxmd.com/read/28336372/doxorubicin-targets-multiple-players-a-new-view-of-an-old-problem
#1
REVIEW
Donato Cappetta, Francesca Rossi, Elena Piegari, Federico Quaini, Liberato Berrino, Konrad Urbanek, Antonella De Angelis
Anthracycline cardiotoxicity remains a serious problem in paediatric and adult cancer survivors, and the advancement of cardio-oncology is a necessary step for an effective care of the patients that experience adverse cardiovascular effects. In this review, we discuss the multiple instruments used by clinicians that constitute the current strategies for primary and secondary prevention aiming at contrasting the onset of early and late doxorubicin-induced cardiotoxic events. The importance of early detection of cardiotoxicity and the following pharmacological therapy has been acknowledged with the emphasis put on impaired diastolic function, an increasingly recognized precocious sign of doxorubicin cardiotoxicity with an emerging scientific and clinical interest...
March 20, 2017: Pharmacological Research: the Official Journal of the Italian Pharmacological Society
https://www.readbyqxmd.com/read/28315122/cardio-oncology-the-nuclear-option
#2
REVIEW
Jorge A Alvarez, Raymond R Russell
PURPOSE OF REVIEW: Cardio-oncology focuses increased effort to decrease cancer treatment-related cardiotoxicity while continuing to improve outcomes. We sought to synthesize the latest in nuclear cardiology as it pertains to the assessment of left ventricular function in preventative guidelines and comparison to other modalities, novel molecular markers of pre-clinical cardiotoxicity, and its role in cardiac amyloid diagnosis. RECENT FINDINGS: Planar ERNA (equilibrium radionuclide angiocardiography) provides a reliable and proven means of monitoring and preventing anthracycline cardiotoxicity, and SPECT ERNA using solid-state gamma cameras may provide reproducible assessments of left ventricular function with reduced radiation exposure...
April 2017: Current Cardiology Reports
https://www.readbyqxmd.com/read/28285949/considerations-in-cardio-oncology-multiple-mobile-left-sided-cardiac-thrombi-in-chemotherapy-induced-cardiomyopathy
#3
Toshinori Minamishima, Kenichi Matsushita, Hiromu Morikubo, Aoi Isaka, Noriko Matsushita, Hidehito Endo, Hiroshi Kubota, Konomi Sakata, Toru Satoh, Hideaki Yoshino
With advances in cancer chemotherapy, the importance of the new clinical discipline of cardio-oncology, which is concerned with the cardiac effects of chemotherapy, is increasing. Herein we describe the case of a 48-year-old woman with a history of breast cancer who presented with symptoms of heart failure due to chemotherapy-induced cardiomyopathy. Treatment for the patient's breast cancer had included surgery and chemotherapy with anthracyclines and trastuzumab. Echocardiography revealed multiple mobile thrombi in the left ventricle and atrium...
March 10, 2017: Journal of Infection and Chemotherapy: Official Journal of the Japan Society of Chemotherapy
https://www.readbyqxmd.com/read/28268088/acute-decompensated-heart-failure-as-a-reason-of-premature-chemotherapy-discontinuation-may-be-independent-of-a-lifetime-doxorubicin-dose-in-lymphoma-patients-with-cardiovascular-disorders
#4
Sebastian Szmit, Wojciech Jurczak, Jan Maciej Zaucha, Monika Długosz-Danecka, Barbara Sosnowska-Pasiarska, Ewa Chmielowska, Monika Joks, Joanna Drozd-Sokołowska, Wanda Knopińska-Posłuszny, Wojciech Spychałowicz, Beata Kumiega, Grzegorz Charliński, Marta Morawska, Grzegorz Słomian
BACKGROUND: Algorithm of anthracycline-based chemotherapy with favourable cardio-oncological outcome should be clearly re-defined for lymphoma patients with significant pre-existing cardiovascular diseases. A clinical benefit of liposomal forms of anthracycline is still debatable. METHODS: Polish registry included observations of 138 lymphoma patients with concomitant cardiovascular disorders who received liposomal doxorubicin as cardioprotective alternative of conventional form...
May 15, 2017: International Journal of Cardiology
https://www.readbyqxmd.com/read/28152766/outcome-analysis-of-breast-cancer-patients-treated-with-cardiotoxic-agents-in-the-community-setting-a-single-institution-experience
#5
Munthir Mansour, Todd W Gress, Maria R B Tria Tirona
213 Background: Anthracyclines and anti-Her-2 targeted therapy are commonly used effective breast cancer treatments. They are known to decrease Left Ventricular Ejection Fraction (LVEF), which may increase patients' morbidity and mortality. There is currently no consensus on post treatment cardiac follow-up. Recent observations suggested that ACEI and B blocker drugs could have cardioprotective effects. We conducted a retrospective study to assess patients' cardiac outcome using post-treatment LVEF follow-up and effect of ACEI and B blocker on cardiac outcome for breast cancer patients who received cardiotoxic agents in our institution...
March 2016: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://www.readbyqxmd.com/read/28029315/left-ventricular-dysfunction-with-trastuzumab-therapy-is-primary-prevention-the-best-option
#6
Paaladinesh Thavendiranathan, Eitan Amir
The Oncology Grand Rounds series is designed to place original reports published in the Journal into clinical context. A case presentation is followed by a description of diagnostic and management challenges, a review of the relevant literature, and a summary of the authors' suggested management approaches. The goal of this series is to help readers better understand how to apply the results of key studies, including those published in Journal of Clinical Oncology, to patients seen in their own clinical practice...
March 10, 2017: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://www.readbyqxmd.com/read/27965861/exercise-to-prevent-anthrcycline-based-cardio-toxicity-exact-in-individuals-with-breast-or-hematological-cancers-a-feasibility-study-protocol
#7
Melanie R Keats, Scott A Grandy, Nicholas Giacomantonio, David MacDonald, Miroslaw Rajda, Tallal Younis
BACKGROUND: Anthracyclines (AC), widely used and effective anticancer agents, are known to induce both acute and chronic declines in cardiovascular health, ranging in severity from asymptomatic, subclinical dysfunction to substantial cardiomyopathy leading to congestive heart failure and death. There is substantial evidence that physical activity, higher levels of cardiorespiratory fitness, and exercise therapy can help prevent cardiovascular disease. Moreover, animal studies have shown that exercise performed concomitantly with AC treatment may attenuate early cardiac damage that results from AC exposure...
2016: Pilot and Feasibility Studies
https://www.readbyqxmd.com/read/27830273/-summary-of-the-esc-position-paper-on-cancer-treatment-and-cardiovascular-toxicity
#8
J Hoog, S Achenbach
The numbers of survivors of cancer have increased as a consequence of advances in chemotherapy; however, the side effects of cancer treatment have become increasingly more important. The most frequent side effects include cardiovascular complications, which can lead to acute and delayed morbidity and mortality, often many years later. The discipline of cardio-oncology deals with the prevention, diagnostics and treatment of cardiovascular diseases caused by cancer therapy. The most important cardiovascular side effects of cytostatic therapy are heart failure due to myocardial dysfunction (cardiotoxicity), coronary artery disease, valvular disease and ventricular arrhythmia as a result of QT extension...
December 2016: Herz
https://www.readbyqxmd.com/read/27721532/benefits-of-antihypertensive-medications-for-anthracycline-and-trastuzumab-induced-cardiotoxicity-in-patients-with-breast-cancer-insights-from-recent-clinical-trials
#9
Katarzyna Rygiel
Advances in oncologic therapies have allowed many patients with breast cancer to achieve better outcomes and longer survival. However, this progress has been tempered by cardiotoxicity, associated with anticancer therapies, ranging from subclinical abnormalities to irreversible life-threatening complications, such as congestive heart failure or cardiomyopathy. In particular, exposure to chemotherapy (CHT), including anthracyclines and trastuzumab, can lead to cardiac dysfunction with short- or long-term consequences, among patients with breast cancer...
September 2016: Indian Journal of Pharmacology
https://www.readbyqxmd.com/read/27694540/the-evolving-field-of-cardio-oncology-beyond-anthracyclines-and-heart-failure
#10
Michael G Fradley
No abstract text is available yet for this article.
September 21, 2016: European Heart Journal
https://www.readbyqxmd.com/read/27686178/deciphering-molecular-aspects-of-interaction-between-anticancer-drug-mitoxantrone-and-trna
#11
Bhumika Ray, Shweta Agarwal, Heena Kadian, Kaweri Gambhir, Parag Sharma, Ranjana Mehrotra
Mitoxantrone (1,4-dihydroxy-5,8-bis[[2-[(2-hydroxyethyl)amino]ethyl]amino]-9,10-anthracenedione) is a synthetically designed antineoplastic agent and structurally similar to classical anthracyclines. It is widely used as a potent chemotherapeutic component against various kinds of cancer and possesses lesser cardio-toxic effects with respect to naturally occurring anthracyclines. In the present study, we have investigated the binding features of mitoxantrone-tRNA complexation at physiological pH using attenuated total reflection-Fourier transform infrared (ATR-FTIR) spectroscopy, circular dichroism (CD) spectroscopy, isothermal titration calorimetry, and UV-visible absorption spectroscopic techniques...
August 9, 2016: Journal of Biomolecular Structure & Dynamics
https://www.readbyqxmd.com/read/27660573/cardio-oncology-a-focused-review-of-anthracycline-human-epidermal-growth-factor-receptor-2-inhibitor-and-radiation-induced-cardiotoxicity-and-management
#12
REVIEW
Jean Domercant, Nichole Polin, Eiman Jahangir
BACKGROUND: Cardio-oncology is a collaborative approach between cardiologists and oncologists in the treatment of patients with cancer and heart disease. Radiation and chemotherapy have played a major role in the decreased cancer-related mortality achieved in the past 2 decades. However, anthracycline-, tyrosine kinase-, and radiation-based therapies are each associated with independent cardiovascular (CV) risks, and these risks are cumulative when these therapies are used in combination...
2016: Ochsner Journal
https://www.readbyqxmd.com/read/27629548/rationale-and-design-of-the-multidisciplinary-team-intervention-in-cardio-oncology-study-titan
#13
Edith Pituskin, Mark Haykowsky, Margaret McNeely, John Mackey, Neil Chua, Ian Paterson
BACKGROUND: Cancer is the leading cause of premature death in Canada. In the last decade, important gains in cancer survival have been achieved by advances in adjuvant treatment. However, many oncologic treatments also result in cardiovascular "toxicity". Furthermore, cardiac risk factors such as hypertension, dyslipidemia, and diabetes mellitus are known to contribute to the progression of cardiac damage and clinical cardiotoxicity. As such, for many survivors, the risk of death from cardiac disease exceeds that of recurrent cancer...
September 15, 2016: BMC Cancer
https://www.readbyqxmd.com/read/27566332/echocardiographic-assessment-of-cardiotoxic-effects-of-cancer-therapy
#14
REVIEW
Wendy J Bottinor, Christopher K Migliore, Carrie A Lenneman, Marcus F Stoddard
Patients with cancer can present with difficult management issues, as the medicine can sometimes cause sequelae destructive to healthy tissue. As this population lives longer, cardiotoxic effects are beginning to emerge, but the early recognition of this signal can prove difficult, with too late a recognition leading to lifelong cardiac impairment and dysfunction. Cardio-oncology can bridge this difficulty, and echocardiography and its newer imaging abilities are proving efficacious in this population. This article will address common sequelae of cardiotoxic treatment regimens and offer recommendations for echocardiographic surveillance...
October 2016: Current Cardiology Reports
https://www.readbyqxmd.com/read/27503589/organization-and-implementation-of-a-cardio-oncology-program
#15
Manuela Fiuza, Leonor Ribeiro, Andreia Magalhães, Ana Rita Sousa, Miguel Nobre Menezes, Marília Jorge, Luís Costa, Fausto José Pinto
Considerable advances in cancer therapies in recent decades have reshaped the prognosis of cancer patients. There are now estimated to be over 20 million cancer survivors in the USA and Europe, numbers unimaginable a few years ago. However, this increase in survival, along with the aging of the patient population, has been accompanied by a rise in adverse cardiovascular effects, particularly when there is a previous history of heart disease. The incidence of cardiotoxicity continues to grow, which can compromise the effectiveness of cancer therapy...
September 2016: Portuguese Journal of Cardiology: An Official Journal of the Portuguese Society of Cardiology
https://www.readbyqxmd.com/read/27170025/high-sensitive-cardiac-troponin-i-facilitates-timely-detection-of-subclinical-anthracycline-mediated-cardiac-injury
#16
Melissa Jones, Peter O'Gorman, Catherine Kelly, Niall Mahon, Maria C Fitzgibbon
Background Anthracycline drugs are effective anticancer agents, but their optimal use is limited in many patients by the associated cardiotoxicity, even at designated safe doses. As conventionally sensitive cardiac troponin-I assays fail to reliably quantify concentrations of cardiac troponin-I below 30 ng/L, we investigated the potential role of high-sensitive cardiac troponin-I in the detection of subclinical cardiomyocyte injury in patients treated with anthracycline agents. Methods Serial high-sensitive cardiac troponin-I concentrations were assessed in 84 patients, receiving anthracycline-containing ( n = 38) and non-anthracycline-containing ( n = 46) regimens...
January 2017: Annals of Clinical Biochemistry
https://www.readbyqxmd.com/read/26828775/new-signal-transduction-paradigms-in-anthracycline-induced-cardiotoxicity
#17
REVIEW
Alessandra Ghigo, Mingchuan Li, Emilio Hirsch
Anthracyclines, such as doxorubicin, are the most potent and widely used chemotherapeutic agents for the treatment of a variety of human cancers, including solid tumors and hematological malignancies. However, their clinical use is hampered by severe cardiotoxic side effects and cancer therapy-related heart disease has become a leading cause of morbidity and mortality among cancer survivors. The identification of therapeutic strategies limiting anthracycline cardiotoxicity with preserved antitumor efficacy thus represents the current challenge of cardio-oncologists...
July 2016: Biochimica et Biophysica Acta
https://www.readbyqxmd.com/read/26826318/clinical-course-and-therapeutic-implications-for-lymphoid-malignancies-in-nijmegen-breakage-syndrome
#18
REVIEW
Agata Pastorczak, Tomasz Szczepanski, Wojciech Mlynarski
Nijmegen breakage syndrome (NBS, MIM #251260) is an autosomal recessive chromosomal instability disorder. Majority of patients affected are of Slavic origin and share the same founder mutation of 657del5 within the NBN gene encoding protein involved in DNA double-strand breaks repair. Clinically, this is characterized by a microcephaly, immunodeficiency and a high incidence of pediatric malignancies, mostly lymphomas and leukemias. Anticancer treatment among patients with NBS is challenging because of a high risk of life threatening therapy-related toxicity including severe infections, bone marrow failure, cardio- and nephrotoxicity and occurrence of secondary cancer...
March 2016: European Journal of Medical Genetics
https://www.readbyqxmd.com/read/26490280/breast-cancer-survivorship-and-cardiovascular-disease-emerging-approaches-in-cardio-oncology
#19
Yu Xie, William J Collins, M William Audeh, Stephen L Shiao, Roberta A Gottlieb, Marc T Goodman, C Noel Bairey Merz, Puja K Mehta
Cardiovascular disease (CVD) and breast cancer cause substantial morbidity and mortality in women and are major public health concerns in the USA. While aggressive screening and targeted, advanced treatment for breast cancer have had a measurable impact on breast cancer survival, treatment is not without significant cardiotoxic effects. Anthracycline-based chemotherapy can lead to left ventricular dysfunction and failure, as well as a decline in exercise tolerance and cardio-pulmonary reserve despite preserved ejection fraction...
December 2015: Current Treatment Options in Cardiovascular Medicine
https://www.readbyqxmd.com/read/26462128/systems-biology-approaches-to-adverse-drug-effects-the-example-of-cardio-oncology
#20
REVIEW
Sherry-Ann Brown, Nicole Sandhu, Joerg Herrmann
Increased awareness of the cardiovascular toxic effects of chemotherapy has led to the emergence of cardio-oncology (or onco-cardiology), which focuses on screening, monitoring and treatment of patients with cardiovascular dysfunctions resulting from chemotherapy. Anthracyclines, such as doxorubicin, and HER2 inhibitors, such as trastuzumab, both have cardiotoxic effects. The biological rationale, mechanisms of action and cardiotoxicity profiles of these two classes of drugs, however, are completely different, suggesting that cardiotoxic effects can occur in a range of different ways...
December 2015: Nature Reviews. Clinical Oncology
keyword
keyword
98870
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"